文献速递糖尿病

持续葡萄糖监测与1型糖尿病成人急慢性并发症及死亡风险:全国队列研究

Continuous glucose monitoring and risks of acute and chronic diabetes-related complications and mortality in adults with type 1 diabetes: a nationwide cohort study.
PubMed 文献 · Diabetologia · 2026-03-21

该研究基于韩国国民健康保险服务队列(2016-2022年),纳入17018例接受强化胰岛素治疗的1型糖尿病成人,比较CGM使用者与非使用者的急慢性并发症及死亡风险。结果显示CGM使用者DKA、ESKD、CVD及全因死亡风险均显著低于非使用者,而严重低血糖风险组间相当;CGM启动后严重低血糖频率较前下降61.5%。

要点

  • CGM使用者DKA、ESKD、CVD及全因死亡风险均显著低于非使用者。
  • CGM使用者与非使用者严重低血糖风险组间无显著差异。
  • CGM启动后严重低血糖频率较前下降61.5%。

核心结论

  • 在1型糖尿病成人中,CGM使用者较非使用者急性与慢性糖尿病相关并发症及全因死亡风险更低。

研究设计与样本

  • 基于韩国国民健康保险服务队列(2016-2022年)的全国性队列研究,纳入接受强化胰岛素治疗的1型糖尿病成人17018例(CGM使用者8509例,非使用者8509例)。

主要发现

  • CGM使用者DKA风险低于非使用者(aHR 0.40;95%CI 0.33,0.48)。
  • CGM使用者ESKD风险低于非使用者(aHR 0.43;95%CI 0.32,0.56)。
  • CGM使用者CVD风险低于非使用者(aHR 0.28;95%CI 0.23,0.33)。
  • CGM使用者全因死亡风险低于非使用者(aHR 0.38;95%CI 0.32,0.46)。
  • CGM使用者与非使用者严重低血糖风险相当(aHR 0.92;95%CI 0.77,1.10)。

关键数值与推荐

  • CGM使用者DKA的aHR为0.40(95%CI 0.33,0.48)。
  • CGM使用者ESKD的aHR为0.43(95%CI 0.32,0.56)。
  • CGM使用者CVD的aHR为0.28(95%CI 0.23,0.33)。
  • CGM使用者全因死亡的aHR为0.38(95%CI 0.32,0.46)。
  • CGM使用者严重低血糖的aHR为0.92(95%CI 0.77,1.10)。

临床怎么用

  • 在1型糖尿病成人强化胰岛素治疗中,CGM使用与DKA、ESKD、CVD及全因死亡风险降低相关。
  • CGM启动后严重低血糖频率较前下降61.5%,DKA和CVD相关住院或急诊就诊频率分别下降60.0%和50.0%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: We investigated the association between continuous glucose monitoring (CGM) and acute and chronic diabetes-related complications and mortality risk in adults with type 1 diabetes. METHODS: This study included adults with type 1 diabetes who received intensive insulin therapy, based on data from the Korean National Health Insurance Service Cohort (2016-2022). The primary outcomes were diabetic ketoacidosis (DKA), severe hypoglycaemia (SH), end-stage kidney disease (ESKD), cardiovascular disease (CVD) and all-cause mortality. Between-group analyses (comparing outcomes between CGM users and non-users) were conducted using Cox proportional hazards regression models, and within-group analyses (comparing outcomes before and after CGM initiation) were performed using paired t tests. RESULTS: A total of 17,018 individuals (8509 CGM users and 8509 non-users) were included. CGM users had lower rates of DKA (adjusted hazard ratio [aHR] 0.40; 95% CI 0.33, 0.48), ESKD (aHR 0.43; 95% CI 0.32, 0.56), CVD (aHR 0.28; 95% CI 0.23, 0.33) and all-cause mortality (aHR 0.38; 95% CI 0.32, 0.46) than non-users. The aHR for SH was comparable between the two groups (aHR 0.92; 95% CI 0.77, 1.10 for users vs non-users). However, among CGM users, the mean frequency of SH decreased by 61.5% after CGM initiation (p<0.001). The frequencies of DKA and CVD-related hospitalisation or emergency department visits also decreased by 60.0% and 50.0%, respectively (p<0.001 for both). CONCLUSIONS/INTERPRETATION: In this nationwide cohort study of adults with type 1 diabetes, CGM users had lower rates of both acute and chronic diabetes-related complications and all-cause mortality compared with non-users.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Kim JY, Kim S, Kim JH, et al. Continuous glucose monitoring and risks of acute and chronic diabetes-related complications and mortality in adults with type 1 diabetes: a nationwide cohort study. Diabetologia. 2026. PMID: 41865177. doi:10.1007/s00125-026-06709-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。